ema semaglutide naion june 2025 The Effect of and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy A new study published in
Description
Based on typical FDA New Drug Application timelines for novel incretin compounds and the Emirates Drug Establishment registration pathway that follows initial regulatory approval, UAE pharmacy availability is unlikely before 2029
When combined with lifestyle changes, it supports long-term weight management
Timeline GLP-1 results occur gradually over several months
It's important to note that the study was small and the patients were mostly white and privately insured, meaning the results may not apply to everyone
Its a valuable tool in our arsenal of treatment options, offering a new level of effectiveness in medical weight loss
